SRR1314958
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.443
- PANCREAS_BETA_CELLS+0.289
- HEDGEHOG_SIGNALING+0.287
- MYOGENESIS+0.241
- SPERMATOGENESIS+0.215
- ESTROGEN_RESPONSE_LATE+0.206
- ESTROGEN_RESPONSE_EARLY+0.171
- APICAL_SURFACE+0.156
- BILE_ACID_METABOLISM+0.155
- UV_RESPONSE_DN+0.150
Top 10 suppressed
- MYC_TARGETS_V1-0.610
- E2F_TARGETS-0.494
- PROTEIN_SECRETION-0.480
- INTERFERON_ALPHA_RESPONSE-0.468
- UNFOLDED_PROTEIN_RESPONSE-0.449
- DNA_REPAIR-0.448
- TGF_BETA_SIGNALING-0.438
- G2M_CHECKPOINT-0.434
- MYC_TARGETS_V2-0.404
- MTORC1_SIGNALING-0.375
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1405007 | GTEX | — | 0.963 |
| 2 | SRR1418127 | GTEX | — | 0.962 |
| 3 | SRR1316297 | GTEX | — | 0.961 |
| 4 | SRR1500868 | GTEX | — | 0.959 |
| 5 | SRR1485542 | GTEX | — | 0.958 |
| 6 | SRR1472323 | GTEX | — | 0.957 |
| 7 | SRR1375976 | GTEX | — | 0.957 |
| 8 | SRR1331751 | GTEX | — | 0.956 |
| 9 | SRR1337864 | GTEX | — | 0.955 |
| 10 | SRR1311575 | GTEX | — | 0.955 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.443 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.289 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.287 | Inavolisib | — uncovered |
| MYOGENESIS | 0.241 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.215 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.206 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.171 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.156 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.155 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.101 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.032 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.028 | Remibrutinib | — uncovered |